BioSpace News Archive

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that it has entered into a clinical trial collaboration and supply agreement with Merck.

Nuvalent, Inc. announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT.

Sage Therapeutics, Inc. and Biogen Inc. presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression, at the 35th European College of Neuropsychopharmacology Congress, taking place October 15-18, 2022, in Vienna, Austria.

Austrian solution provider Single Use Support GmbH is expanding its product portfolio with new single-use bioprocess containers under the brand name IRIS.

Replay today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy.

Anavex Life Sciences Corp. today announced that the company will present Phase 2b/3 ANAVEX®2-73-AD-004 data of oral ANAVEX®2-73 for Early Alzheimer’s Disease at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022 in San Francisco, CA and publish the findings in a peer-reviewed medical journal.

Mereo BioPharma Group plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966).

Zynerba Pharmaceuticals, Inc. presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington, D.C.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

NuVasive, Inc. today announced it will continue its partnership with EUROSPINE as a gold sponsor and will attend EUROSPINE 2022 held October 19 to 21 in Milan.